Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421583 | 0.83 | SIRT3 (0.42) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL8128501 | 0.78 | KDM4E (0.59) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL2645253 | 0.78 | TDP1 (0.57) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL2873278 | 0.78 | P2RX1 (0.37) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL17438485 | 0.77 | TDP1 (0.55) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL17438491 | 0.77 | TDP1 (0.55) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| Hydrochloric Acid SCHEMBL7960128 | 0.77 | KDM4E (0.57) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL17984632 | 0.77 | GAA (0.48) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL16897000 | 0.77 | CCNC (0.43) | KDM4ETDP1ALDH1A1KDM4CMEN1 | |
| SCHEMBL11001665 | 0.77 | TDP1 (0.50) | KDM4ETDP1ALDH1A1KDM4CMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009058274-A1 | CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING COMPOSITION COMPRISING AMIDOXIME COMPOUNDS AND ASSOCIATED METHOD FOR USE | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | claimed |
| WO-2022170075-A1 | AUXINIC HERBICIDES AND METHODS OF USE THEREOF | CORTEVA AGRISCIENCE LLC (US) | 2022-08-11 | — | — | WO | disclosed |
| CN-102118972-B | Novel modulators of sphingosine phosphate receptors | SCRIPPS RESEARCH INST | 2015-06-10 | — | — | CN | disclosed |
| CN-102239146-A | Novel compounds as calcium channel blockers | ABBOTT LAB | 2011-11-09 | — | — | CN | disclosed |
| CN-102216277-A | Substituted benzamides as cannabinoid receptor ligands | ABBOTT LAB | 2011-10-12 | — | — | CN | disclosed |
| CN-102118972-A | Novel modulators of sphingosine phosphate receptors | SCRIPPS RESEARCH INST | 2011-07-06 | — | — | CN | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2291080-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | The Scripps Research Institute (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-2207750-A1 | STABILIZATION OF HYDROXYLAMINE CONTAINING SOLUTIONS AND METHOD FOR THEIR PREPARATION | EKC Technology, INC. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009151529-A9 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-04-08 | — | — | WO | disclosed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2009151529-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009085072-A1 | COMPOSITION COMPRISING CHELATING AGENTS CONTAINING AMIDOXIME COMPOUNDS | EKC TECHNOLOGY, INC (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009058274-A1 | CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING COMPOSITION COMPRISING AMIDOXIME COMPOUNDS AND ASSOCIATED METHOD FOR USE | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058272-A1 | COPPER CMP POLISHING PAD CLEANING COMPOSITION COMPRISING OF AMIDOXIME COMPOUNDS | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058273-A1 | STABILIZATION OF HYDROXYLAMINE CONTAINING SOLUTIONS AND METHOD FOR THEIR PREPARATION | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058287-A1 | PROCESS OF PURIFICATION OF AMIDOXIME CONTAINING CLEANING SOLUTIONS AND THEIR USE | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058278-A1 | METHODS OF CLEANING SEMICONDUCTOR DEVICES AT THE BACK END OF LINE USING AMIDOXIME COMPOSITIONS | EKC TECHNOLOGY, INC (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058275-A1 | METHODS OF POST CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING USING AMIDOXIME COMPOSITIONS | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | KDM4E 1133/4885TDP1 2342/4885ALDH1A1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.